EligibleTrials

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

Recruiting · NCT07483294 · Interventional (participants receive a specific treatment) · Lead sponsor: Northwell Health

View the official record on ClinicalTrials.gov →
Schizophrenia

Interventions studied

aripiprazolerisperidone

What this trial is about

This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and subsequently be treated with either risperidone or aripiprazole for 12 weeks. Clinical assessments for psychotic symptoms will be followed multiple times during the treatment until the 12th week. Data analysis will be conducted at the Psychiatric Research Unit of the Zucker Hillside Hospital.

Who can take part

Age range
15 Years to 40 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.